key: cord-0779504-nkiimo95
authors: Smith, Elizabeth; Zhen, Wei; Manji, Ryhana; Schron, Deborah; Duong, Scott; Berry, Gregory J.
title: Analytical and Clinical Comparison of Three Nucleic Acid Amplification Tests for SARS-CoV-2 Detection
date: 2020-05-15
journal: bioRxiv
DOI: 10.1101/2020.05.14.097311
sha: ea3a6005c7d285432c3d5103ada9453d9aa75331
doc_id: 779504
cord_uid: nkiimo95

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was first identified in December 2019 and has quickly become a worldwide pandemic. In response, many diagnostic manufacturers have developed molecular assays for SARS-CoV-2 under the Food and Drug Administration (FDA) Emergency Use Authorization (EUA) pathway. This study compared three of these assays: the Hologic Panther Fusion SARS-CoV-2 assay (Fusion), the Hologic Aptima SARS-CoV-2 assay (Aptima) and the BioFire Diagnostics COVID-19 test (BioFire), to determine analytical and clinical performance, as well as workflow. All three assays showed a similar limit of detection (LOD) using inactivated virus, with 100% detection ranging from 500-1,000 genome equivalents/ml, whereas use of a quantified RNA transcript standard showed the same trend, but had values ranging from 62.5 to 125 copies/ml, confirming variability in absolute quantification of reference standards. The clinical correlation found that the Fusion and BioFire assays had a positive percent agreement (PPA) of 98.7%, followed by the Aptima assay at 94.7% when compared to the consensus result. All three assays exhibited 100% negative percent agreement (NPA). Analysis of discordant results revealed that all four samples missed by the Aptima assay had Ct values >37 on the Fusion assay. In conclusion, while all three assays showed similar relative LODs, we showed differences in absolute LODs depending on which standard was employed. In addition, the Fusion and BioFire assays showed better clinical performance, while the Aptima assay showed a modest decrease in overall PPA. These findings should be kept in mind when making platform testing decisions.

assays showed a similar limit of detection (LOD) using inactivated virus, with 100% detection ranging from 23 500-1,000 genome equivalents/ml, whereas use of a quantified RNA transcript standard showed the same 24 trend, but had values ranging from 62.5 to 125 copies/ml, confirming variability in absolute quantification 25 of reference standards. The clinical correlation found that the Fusion and BioFire assays had a positive 26 percent agreement (PPA) of 98.7%, followed by the Aptima assay at 94.7% when compared to the 27 consensus result. All three assays exhibited 100% negative percent agreement (NPA). Analysis of 28 discordant results revealed that all four samples missed by the Aptima assay had Ct values >37 on the 29 Fusion assay. 30

In conclusion, while all three assays showed similar relative LODs, we showed differences in 31 absolute LODs depending on which standard was employed. In addition, the Fusion and BioFire assays 32 showed better clinical performance, while the Aptima assay showed a modest decrease in overall PPA. 33

These findings should be kept in mind when making platform testing decisions. 34

Specimen collection and storage. Nasopharyngeal (NP) swabs were obtained from patients with clinical 74 signs/symptoms of COVID-19. Each collection used a sterile swab made from Dacron, rayon or nylon which 75 was placed into sterile 3 ml universal transport medium (UTM-various manufacturers) after collection. 76

Samples were then transported at room temperature and were stored at 2-8⁰C for up to 72 hours and 77 tested as soon as possible after collection. For the retrospective sample set, after routine patient testing, 78 aliquots of samples were taken and stored at -80⁰C until testing of the three comparator NAATs could 79 occur. 80 81

Samples were selected from specimens received for routine SARS-CoV-2 testing between April and May 83 of 2020. The selection included symptomatic patients of all genders and ages. A total of 150 84 nasopharyngeal (NP) samples (75 negative and 75 positive) were used for this study: 101 retrospective 85 specimens (51 negative, 50 positive) and 49 prospective, fresh specimens (24 negative, 25 positive). 86

Specimens were selected to represent our laboratory's positivity rate at the time this study was designed 87 (50 -60% at beginning of April 2020) and also included positive specimens spanning the range of positivity, 88 including those with low viral loads (characterized by high cycle threshold (Ct) values obtained by results 89 from initial clinical testing). The 101 retrospective specimens were initially tested per routine patient care 90 and then immediately aliquoted and frozen at -80⁰C, remaining frozen until this study was performed. 91

Retrospective sample aliquots were thawed and immediately tested on the Fusion, Aptima, and BioFire 92 systems. Testing for prospective samples was performed within 48 hours of collection. Prospective 93 samples were run on the Fusion, Aptima and BioFire using the original UTM sample and aliquoted directly 94 into Hologic Lysis tubes and into BioFire Sample Injection Vial. This work was conducted as a quality 95 6 Hologic Panther Fusion® SARS-CoV-2 assay (Fusion). The Fusion assay (Hologic, Inc., San Diego, CA) was 98 performed on the Panther Fusion instrument according to the manufacturer's instructions for use. This 99 assay targets two unique regions of the ORF1ab section of the SARS-CoV-2 viral genome. A 500 µL aliquot 100 of the primary NP swab specimen is transferred into a Specimen Lysis Tube containing 710 µL lysis buffer 101 and is then loaded onto the Panther Fusion instrument. From this tube, the instrument removes 360 µl 102 for extraction. Each specimen is processed with an internal control (IC), which is added via the working 103

Panther Fusion Capture Reagent-S. Nucleic acid is purified using capture oligonucleotides and a magnetic 104 field, eluted in 50 µl, and 5 µl of the eluted nucleic acid is added to a Panther Fusion reaction tube. The 105 Each specimen is processed with an IC, which is added via the working Target Capture Reagent. Nucleic 119 acid is purified using capture oligonucleotides and a magnetic field, and the purified nucleic acid used as 7 template for the TMA reaction. After amplification, chemiluminescent probes hybridize to amplicons and 121 emit light measured by a luminometer in relative light units (RLUs). The IC signal and SARS-CoV-2-specific 122 signal are differentiated by kinetic profiles of the labeled probes (rapid vs slow). Assay results are 123 determined by a cut-off based on the total RLU and the kinetic curve type. Table 1 ) for testing across the different platforms. The same process was 145 followed for the Exact Diagnostics control, which had starting concentration of 200,000 copies/ml and 146 was diluted to make the same concentration of serial dilutions as those performed for the BEI material. 147 LOD was defined as the lowest dilution at which all replicates were positive (100% detection rate). 148 149 Workflow Evaluation. Workflow was evaluated using a calibrated timer to measure the time needed for 150 each step being evaluated, including hands-on time (HoT), assay run time and total turnaround time (TAT). 151

HoT, assay run time, and TAT were calculated using the throughput of samples per run. algorithm per the instructions for use for each assay. Using these criteria, the LOD using inactivated SARS-170 CoV-2 virus was 1,000 GE/ml for the Fusion assay, 500 GE/ml for the Aptima assay, and 500 GE/ml for the 171 BioFire test ( Table 1 ). In addition, the LOD as determined using the Exact Diagnostics synthetic RNA 172 transcript was 62.5 copies/ml for both the Fusion and Aptima and 125 copies/ml for the BioFire. buffer mixing, addition of sample/buffer to the pouch, and loading onto the instrument. These additional 207 step for BioFire account for the increased HoT per specimen as seen in Table 4 . 208

The present study compared the analytical sensitivity (LOD), clinical performance, and workflow 210 of three SARS-CoV-2 NAATs in 150 NP swab specimens. Our two independent LOD analyses revealed that 211 while all 3 assays had an LOD that was within 1 dilution factor of each other within a given control material, 212 absolute LODs with quantified inactivated virus (500-1,000 GE/ml) were several-fold higher than the 213 value obtained when using quantified synthetic RNA (62.5-125 copies/ml). This difference in absolute 214 LOD values reflects the inherent difficulty in comparing standards that have been prepared and 215 quantitated differently and have very high stock concentrations requiring significant dilutions for LOD 216 panel testing (i.e., any quantification error and/or pipetting error of the stock will be magnified in a 217 dilution series). Of interest, the LOD calculations for BioFire using the synthetic RNA standard only showed 218 amplification in two of three gene targets, since ORF1ab is included in the Exact diagnostics control, but 219 ORF 8 is not included. Considering this discrepancy, the decreased LOD relative to the Fusion and Aptima 220 when using the quantified synthetic RNA is likely due to the lack of ORF 8 target material. (GSD-3, 4, 6, and 48) had Ct values ranging from 230 37.3-40.5, suggesting that the Aptima assay is slightly less sensitive than the Fusion and Biofire assays. Of and resulted as positive as per the EUA IFU, suggesting that these were also weak positives on the BioFire 233 assay. 234

Workflow comparisons between the Fusion and the Aptima were quite similar, both being optimal 235 in high-volume testing situations (> 1,000 tests/24 hours), whereas the BioFire assay had an advantage of 236

fast sample to answer time, allowing for faster detection and diagnosis that is useful in urgent situations. 237

Other comparator studies of the Fusion assay have recently been reported, including: a study 238 comparing Fusion to the modified CDC assay, GenMark ePlex, DiaSorin Simplexa (6); a study comparing 239

Cepheid, ID NOW, and GenMark using Fusion as the reference standard (7); a study comparing Fusion, 240

Cepheid, DiaSorin, cobas, and a laboratory-developed test (LDT) (8) ; and a study comparing Fusion to an 241 in-house LDT targeting the envelope gene (9). In general, these reports show that the Fusion SARS-CoV-2 242 assay is comparable, if not superior, to other molecular platforms available for SARS-CoV-2 testing. In 243 particular, these evaluations showed that Fusion, DiaSorin and Cepheid tended to have better analytical 244 sensitivity and fewer false negatives in clinical testing than other assays. The low rate of false negatives is 245 a critical performance aspect, as missed positive results allow for further spread of the disease and 246 potential patient mismanagement. These comparison studies, while not clinical trials as would be typical 247 of new FDA-cleared IVD assays, have provided a window into the relative real world clinical performance 248 characteristics of these assays, which has been a significant knowledge gap since these SARS-CoV-2 EUA 249 molecular assays first became available. Among these knowledge gaps are relative performance data for 250 the Aptima and BioFire tests. To our knowledge, this is the first report comparing both the Aptima and 251

BioFire assay to any other NAAT for SARS-CoV-2 detection. 252

It is worth noting that the LOD for the Fusion SARS-CoV-2 assay as determined in this study was 253 1,000 GE/ml when using inactivated virus, while the LOD determined in a previous study by our laboratory 254 was 83 ±36 copies/ml (6) and an additional LOD study performed as part of this study once again using 255 the same synthetic quantified RNA standard also previously published showed a comparable LOD of 62.5 256 LOD values when using different standards, specifically inactivated virus vs. synthetic RNA standards. 258

This study does have limitations, being a single site study with a limited number of NP swab 259 specimens (n = 150) included in the clinical evaluation. However, this specimen set was selected to be 260 representative of our patient population (including samples from patients of all ages and both genders) 261 and positivity rate (50-60% in the beginning of April 2020), and included samples with a range of viral 262 loads (low, moderate, high). Some initial equivocal or invalid results (n=3) by BioFire and Fusion required 263

retesting, but only 1 remained unresolved on retest and was removed from the agreement analysis for 264 the Fusion assay. 265

In conclusion, our data show that the Fusion, Aptima and BioFire SARS-CoV-2 NAATs exhibit 266 similar LODs, even when tested using two different quantified standards. In addition, the Fusion and 267 125 copies/ml GE, genomic equivalents; LOD, limit of detection 313 a. The LOD by positivity rate for each NAAT is highlighted in bold. 314 b. Numbers of replicates at each dilution that gave initial equivocal results and required repeat testing: 0 315

(1,000 GE/ml), 1 (500 GE/ml), 1 (250 GE/ml), 5 (125 GE/ml), 2 (62.5 GE/ml), 0 (31.3 GE/ml). 316 c. Numbers of replicates at each dilution that gave initial equivocal results and required repeat testing: 0 317

(1,000 copies/ml, 500 copies /ml and 250 copies /ml), 2 (125 copies /ml), 6 (62.5 copies /ml), 4 (31.3 318 copies/ml). 319 

First Case of 2019 Novel Coronavirus in the United States

Centers for Disease Control and Prevention Web site

Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering at Johns

Coronavirus Disease 2019-(COVID-19) People Who

Are at Higher Risk for Severe Illness

Report of the WHO-China Joint Mission on Coronavirus Disease

Comparison of Four Molecular In Vitro Diagnostic Assays for

Platforms for the Detection of SARS-CoV-2

Commercially Available and Laboratory Developed Assays for in vitro Detection of SARS-CoV-2 in

Panther Fusion and a laboratory-developed test targeting the envelope gene for detection of

The measurement of observer agreement for categorical data

Interrater reliability: the kappa statistic